FBP1 and hepatocellular carcinoma: Biocompatible nanoparticles have been used as EV mimics to replenish FBP1 (gluconeogenesis-related enzyme) expression in recipient hepatocytes and stimulate PKLR upregulation in hepatocyte-derived EVs, alleviating gluconeogenic suppression, counteracting tumorigenic effects, and enhancing NK cytotoxicity in a diethylnitrosamine-induced mouse model of HCC [34].